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ABSTRACT
Background    Cutaneous mastocytosis is a disorder 
characterized by the proliferation of mast cells in the 
skin. Melanoma inhibitory activity (MIA) is a serum 
marker for malignant melanoma. However, it has not 
been known on MIA expression of cutaneous mastocy-
tosis. 
Methods    We investigated the expression of MIA in 
4 child patients with cutaneous mastocytosis immuno-
histochemically and serum MIA level in 1 patient by 
enzyme-linked immunosorbent assay. 
Results    Histopathological examination revealed dif-
fuse mast cell infiltration in the dermis. MIA was posi-
tive for infiltrating mast cells in all patients. Serum level 
of MIA was elevated in 1 patient. 
Conclusion    Although it was difficult to assess the 
significance of elevated serum levels of MIA in child 
patients, MIA was expressed on infiltrating mast cells in 
our study. Based on our findings, mast cell-derived MIA 
might be related to the formation of pigmented regions 
in cutaneous mastocytosis. 
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Mastocytosis is a disorder characterized by the prolif-
eration and accumulation of mast cells in the skin and/
or other organs (systemic mastocytosis). It is known 
that about 80% of patients are cutaneous mastocytosis.1 
Cutaneous mastocytosis is classified into urticaria pig-
mentosa, solitary mastocytoma and diffuse cutaneous 
mastocytosis. Melanoma inhibitory activity (MIA) is an 
11-kD protein that is used as a serum marker for malig-
nant melanoma.2 Recently, we have shown that MIA is 
expressed on mast cells of neurofibroma in patients with 
neurofibromatosis type 1 (NF1).3 However, it has not 
been clear on MIA expression of cutaneous mastocyto-
sis. Therefore, we investigated the expression of MIA 
in 4 patients with cutaneous mastocytosis. We herein 
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report an expression of MIA on mast cells in patients 
with cutaneous mastocytosis and discuss its clinical sig-
nificance.
 
 
MATERIALS AND METHODS
Four patients with cutaneous mastocytosis were studied. 
Immunohistochemistry of formalin-fixed and paraffin-
embedded sections was performed by using the standard 
automated avidin-biotin complex method. The sections 
were incubated with anti-MIA antibody (5 µg/mL, R&D 
Systems, Minneapolis, MN) for 30 min at room temper-
ature. They were then incubated for 30 min with a uni-
versal secondary antibody with a RED Map kit (Ventana 
Medical Systems, Tucson, AZ). Toluidine-blue staining 
was also performed. Serum MIA level was assayed by 
using an MIA enzyme-linked immunosorbent assay kit 
(Roche, Mannheim, Germany).
 
RESULTS
Patient reports 
Patient 1: A 1-year-old boy presented with multiple 
brown macules on the trunk (Fig. 1a). His mother had 
noticed pigmented macules 8 months before presenta-
tion. Since the number of the region had increased, he 
was referred to our department. On physical examina-
tion, Darier’s sign was positive on the macule. Family 
histories were unremarkable. Based on clinical and 
histopathological examinations, a diagnosis of urticaria 
pigmentosa was made.
 
Patient 2: A 2-year-old boy presented with a 20-month 
history of multiple brown macules on the abdomen and 
lower extremities. Darier’s sign was positive on the mac-
ule. Based on clinical and histopathological examina-
tions, a diagnosis of urticaria pigmentosa was made.  
 
Patient 3: An 8-month-old boy presented with a brown 
nodule, 14 × 7 mm in size on the right side of abdomen 
(Fig. 1b). Based on clinical and histopathological exami-
nations, a diagnosis of solitary mastocytoma was made.
 
Patient 4: A 1-year and 9-month-old boy presented with 
a 14-month history of multiple brown macules on the ex-
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Fig. 2. Histopathological examination. 
a: Diffuse mast cell infiltration in the dermis in Patient 1 (hematoxylin and eosin). Bar = 500 µm. 
b: Infiltrating cells are positive for toluidine-blue staining in Patient 4. Bar = 250 µm. 
c: Most of mast cells are positive for melanoma inhibitory activity in Patient 1. Bar = 500 µm.
Fig. 1. Clinical features in Patients 1, 3 and 4. 
a: Multiple reddish-brown macules on the back in Patient 1.  
b: A brown nodule on the right side of abdomen in Patient 3.  
c: Multiple brown macules on the extremities in Patient 4. 
tremities (Fig. 1c). Based on clinical and histopathologi-
cal examinations, a diagnosis of urticaria pigmentosa 
was made. There was no evidence of systemic involve-
ment in all patients.
 
Histopathology 
Histopathological examination revealed a diffuse mast 
cell infiltration in the dermis in all patients (Fig. 2a: Pa-
tient 1). Toluidine-blue staining showed metachromaric 
granules in the infiltrating cells (Fig. 2b: Patient 4). Im-
munohistochemically, most of infiltrating mast cells 
were strongly positive for MIA (Fig. 2c: Patient 1). 
 
Serum level of MIA 
Serum level of MIA was 21.5 ng/mL in Patient 4 (normal, 
healthy adult < 8.8 ng/mL).4 
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MIA in mastocytosis
Table 1. Cutaneous mastocytosis in this report  
 Pa-   Diag- MIA Serum MIA 
tient Age Sex nosis staining (ng/mL)
 1 1 yr Male UP + ND
2 2 yr Male UP + ND
3 8 mo Male CM + ND
4 1 yr 9 mo Male UP + 21.5
 CM, cutaneous mastocytoma; MIA, melanoma inhibitory activity; 
ND, not done; UP, urticaria pigmentosa.
The results of these patients are shown in Table 1. 
  
DISCUSSION
Mastocytosis is a rare disease characterized by the pro-
liferation of mast cells in tissues. In children, mast cell 
hyperplasia is restricted to the skin in most patients in 
contrast to adult patients with systemic involvement.5 It 
is known that childhood-onset mastocytosis often goes 
into remission. Since we have previously found that 
MIA is expressed on mast cells of neurofibroma in pa-
tients with NF1,3 we were interested in MIA expression 
in mastocytosis. As expected, MIA was also expressed 
on mast cells in child patients with cutaneous mastocy-
tosis. It has been reported that blood serotonin levels are 
related to clinical symptoms.6 In addition, it is known 
that elevation of basal tryptase levels are risk factors for 
anaphylaxis.7 Since MIA might be a potential biomarker 
in cutaneous mastocytosis, we investigated serum levels 
of MIA in 1 patient. Serum level of MIA was actually 
elevated in those patients. However, it has been reported 
that serum levels of MIA in children were usually el-
evated compared with those in adults because MIA is 
also expressed in chondrocytes.4 Therefore, it was diffi-
cult to assess the significance of elevated serum levels of 
MIA in child patients with cutaneous mastocytosis. The 
mutations of c-kit has been identified in adult-, but not 
in childhood-onset mastocytosis.8 Since MIA was also 
expressed on mast cells in normal skin (not shown) as 
well as neurofibromas in NF1, the expression may not be 
specific for mast cells in child-onset cutaneous mastocy-
tosis. Although the mechanisms of MIA expression on 
mast cells are unknown, it has been reported that MIA 
shares structural homologies with some integrins and 
has a function for an inhibition of apoptosis in melano-
cytic cells.9 In addition, the transcription factor, SOX10 
has been highly relevanted for melanoma development 
and survival, and that SOX10 inhibition reduced MIA 
expression and promoter activity.10 Recently, it has been 
reported that the risk for malignant melanoma among 
patients with systemic mastocytosis appeared higher 
than in the general population.11 Mast cells would inter-
act with melanocytes through the release of cytokines. 
But the direct connection with the MIA is unidentified 
at present.  Further studies will be necessary to elucidate 
the effect of MIA with melanocytes from cutaneous 
mastocytosis. 
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